Compare VNET Group Inc (VNET) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VNET Group Inc vs GeneDx Holdings Corp — how do they compare? VNET Group Inc trades at $7.7 (market cap $2.19B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: VNET Group Inc is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| VNET | WGS | |
|---|---|---|
Market Cap | $2.19B | $1.80B |
Sector | Technology | Technology |
52-Week High | $14.03 | $167.51 |
52-Week Low | $7.34 | $34.51 |
Enterprise Value | $5.32B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNET trades at $7.675, up 3.86% today, but faces bearish technical signals with 15 sell indicators against 0 buys. The company reported a Q1 2026 net loss of $1.20 per share, missing estimates, while revenue reached $390.13 million. Despite negative profitability margins, analyst consensus remains 62.5% buy-rated, citing strategic investor entry and AI-driven data center demand as growth catalysts.
The outlook hinges on execution of its data center capacity pipeline to reverse losses. Risks include persistent negative earnings, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic given the 54% average price target upside, but profitability improvement is critical for sustained momentum.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
